• Puromycin dihydrochloride: Mechanism, Evidence & Workflow Us

  2026-07-08

  Puromycin dihydrochloride is a potent aminonucleoside antibiotic and protein synthesis inhibitor used in molecular biology. It enables rapid selection of pac gene-expressing cell lines and is widely applied for translation process studies and ribosome function analysis. This article details its mechanism, validated benchmarks, and optimal workflow integration.

• Monomethyl Auristatin E (MMAE): Redefining Targeted Cancer P

  2026-07-07

  Explore how Monomethyl auristatin E (MMAE) advances antibody-drug conjugate payload innovation for overcoming tumor plasticity and therapy resistance. This article offers a deep dive into MMAE’s mechanisms and actionable guidance for translational cancer research.

• Porous Graphene Mass Spectrometry Imaging Reveals Brain Lipi

  2026-07-07

  This study introduces laser-induced graphene (LIG) films as an advanced substrate for matrix-free laser desorption/ionization mass spectrometry imaging (LDI-MSI), enabling unprecedented spatial and temporal resolution in metabolic mapping. The findings uncover dynamic, lateralized changes in brain lipid metabolism following acute ethanol intoxication in mice, offering insights into neurochemical asymmetry and substrate innovation for high-resolution signal transduction research.

• Iptacopan (LNP023): Reliable Factor B Inhibition for Complem

  2026-07-06

  This article delivers a scenario-driven, evidence-based analysis of Iptacopan (LNP023, SKU C8699) for robust alternative complement pathway inhibition in biomedical research. Drawing on peer-reviewed data and best practices, it addresses assay reproducibility, selectivity, and vendor reliability, enabling scientists to confidently design and interpret complement activation studies.

• Telmisartan as an Angiotensin II Receptor Antagonist: Applie

  2026-07-06

  Leverage Telmisartan's unique properties as a potent angiotensin II receptor antagonist for precise hypertension and cardiac hypertrophy modeling. This article details optimized experimental workflows, troubleshooting strategies, and the latest mechanistic insights, ensuring reproducible results in cardiovascular disease research.

• LDN-193189: Pushing BMP Pathway Inhibition into Neural and B

  2026-07-05

  Discover how LDN-193189, a leading ALK inhibitor, is transforming BMP signaling research in neural and epithelial systems. This article uniquely bridges advanced molecular inhibition with new in vitro models, offering nuanced insights for assay development.

• Aclacinomycin A in Nucleolar DNA Damage: Mechanistic Insight

  2026-07-04

  Explore how Aclacinomycin A (Aclarubicin) uniquely models nucleolar DNA damage and persistent rDNA lesions, advancing cancer and genome stability research. This article delivers mechanistic depth and protocol guidance for sophisticated assay development.

• tFUS Mitigates Post-Stroke Neuroinflammation via SHP2 Pathwa

  2026-07-03

  This study reveals that transcranial focused ultrasound stimulation (tFUS) reduces neuroinflammation after ischemic stroke by upregulating the Nespas/miR-383-3p/SHP2 pathway, leading to suppression of the NLRP3 inflammasome. The findings clarify a mechanistic link between non-invasive neuromodulation and inflammation control, highlighting SHP2 as a promising target for post-stroke interventions.

• SU6656 Src Tyrosine Kinases Inhibitor: Applied Protocols & I

  2026-07-03

  SU6656, a selective Src tyrosine kinases inhibitor, is redefining stem cell differentiation and radiotherapy workflows. By leveraging precise protocol parameters and troubleshooting strategies, researchers can achieve higher efficiency in platelet biomanufacturing and enhance radiotherapy responses, as demonstrated by recent studies and APExBIO’s robust supply chain.

• Dual Small Molecule Strategy for Lacrimal Gland Regeneration

  2026-07-02

  The reference study introduces a defined, serum-free culture system using two small molecules—Y27632 and SB 431542—to robustly expand and differentiate mouse lacrimal gland epithelial cells (LGECs) in vitro. This innovation accelerates lacrimal gland injury repair in vivo and establishes a practical foundation for regenerative applications in ocular surface disease.

• GLT-1 Upregulation Counters TBI via CB1-CREB Pathway Inhibit

  2026-07-02

  This study demonstrates that increasing GLT-1 expression in astrocytes mitigates neuronal apoptosis and cognitive deficits after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. The findings illuminate a molecular mechanism linking endocannabinoid activity, glutamate regulation, and neuroprotection, suggesting new approaches for TBI intervention.

• Vacuolin-1: Redefining Lysosomal Exocytosis Inhibition in Di

  2026-07-01

  Explore how Vacuolin-1, a potent lysosomal exocytosis inhibitor, enables precise manipulation of membrane fusion and repair processes in disease models. This article uniquely analyzes assay design and translational strategies, expanding beyond existing mechanistic studies.

• Demethyleneberberine: Applied Workflows and Troubleshooting

  2026-07-01

  Demethyleneberberine (DMB) stands out as a versatile, multi-pathway modulator for inflammation, neurodegeneration, and cancer research. This guide provides actionable protocols, optimization tips, and mechanistic insights—enabling researchers to leverage DMB's unique properties in cell and animal models with confidence.

• Oral Iptacopan Monotherapy Rapidly Controls Hemolysis in PNH

  2026-06-30

  This open-label phase 2 study demonstrates that Iptacopan (LNP023), a selective oral complement factor B inhibitor, rapidly normalizes hemolytic markers and reduces transfusion requirements in treatment-naïve PNH patients. The findings offer robust evidence for the clinical utility of alternative pathway C3bBb inhibition and highlight the translational potential of Iptacopan in complement-mediated hemolytic disorders.

• Iptacopan (LNP023): Transforming Complement Pathway Inhibiti

  2026-06-30

  This article delivers advanced guidance for translational researchers exploring the alternative complement pathway. It integrates mechanistic insights, experimental strategies, and protocol parameters for Iptacopan (LNP023), a next-generation oral factor B inhibitor. Drawing on recent reference studies and real-world disease models, it frames the future of complement therapeutics, positioning APExBIO’s Iptacopan at the forefront of translational innovation.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page